ClinicalTrials.gg
TerminatedNCT03744910IMAGINEUpdated Jul 23, 2025Results posted

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

A Phase 3 interventional study of Clazakizumab and Physiologic saline solution in Antibody-mediated Rejection, sponsored by CSL Behring. Terminated at 142 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment

Why this study was terminated
Early stop for lack of efficacy/futility (at Interim analysis)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This trial investigates the efficacy and safety of clazakizumab [an anti-interleukin (IL)-6 monoclonal antibody (mAb)] for the treatment of CABMR in recipients of a kidney transplant.

02

Conditions studied

  • Antibody-mediated Rejection

Keywords

  • Chronic Active
  • Antibody-mediated Rejection (AMR)
03

In context

Lead sponsor

CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.

First submitted after CSL Behring became part of CSL Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years.

    1. Living donor/deceased donor kidney transplant recipients ≥6 months from time of transplant.
    2. Diagnosis of CABMR determined by kidney and the presence of HLA DSA using single-antigen bead-based assays. For eligibility, kidney biopsy must not be older than 12 months and DSA analysis must be performed no longer than 6 months prior to the start of Screening.

      NOTE: • Within 3 months prior to the start of Screening, treatments for ABMR or TCMR, with the exception of *, are not allowed (see Exclusion Criterion 3).

      • If treatment for ABMR (including CABMR) or TCMR (other than steroids*) was given between 3 to 12 months of Screening, a repeat kidney biopsy and DSA analysis are required at least 6 weeks after the end of treatment to confirm continuing CABMR and presence of HLA DSA and to determine eligibility.

      * A maximum dose of 2g of methylprednisolone intravenously (or dose equivalent of other steroids), followed by a taper to the original maintenance steroid dose is allowed.

      The following histopathologic and serologic diagnostic criteria (based on Banff 2015 criteria [Loupy et al, 2017]) must be met for inclusion:

      1. Morphologic evidence of chronic tissue injury, as demonstrated by transplant glomerulopathy (TG) (cg) > 0). Biopsies without evidence of chronic tissue injury on light microscopy, but with glomerular basement membrane double contours on electron microscopy (cg1a) are eligible.
      2. Evidence of current/recent antibody interaction with vascular endothelium, including 1 or more of the following:

      i. Linear C4d staining in peritubular capillaries or medullary vasa recta (Banff scores C4d2 or C4d3 by immunofluorescence on frozen sections, or C4d > 0 by immunohistochemistry on paraffin sections).

      ii. At least moderate microvascular inflammation ([glomerulitis score, g + peritubular capillaritis score, ptc] ≥ 2) in the absence of recurrent or de novo glomerulonephritis, although in the presence of acute TCMR, borderline infiltrate, or infection, ptc ≥ 2 alone is not sufficient and g must be ≥ 1.

      NOTE: The local pathologist's diagnosis must be reviewed by a central pathologist to confirm eligibility for entry into the study. Biopsies with other histopathologic changes (eg, BKV nephropathy or recurrent glomerulonephritis) may be eligible if concurrent CABMR changes (as detailed above) are present and determined to be the predominant cause of renal dysfunction.

      c. Serologic evidence of circulating HLA DSA. NOTE: The local laboratory DSA results must be reviewed and confirmed by the central HLA reviewer during the screening period.

    3. Written obtained from subject (or legally acceptable representative) before any trial-related procedures.

Exclusion criteria

  1. Multi-organ transplant recipient (except for simultaneous kidney-pancreas or previous multiple kidney transplants) or cell transplant (islet, bone marrow, stem cell) recipient.

    1. Treatment for ABMR (including CABMR) or TCMR within 3 months prior to the start of screening with the exception of .
    2. Received T cell depleting agents (e.g., alemtuzumab, anti-thymocyte globulin) within 3 months prior to the start of screening.
    3. Pregnant, breastfeeding, or unwillingness to practice adequate .
    4. Active tuberculosis (TB) or history of active TB.
    5. History of (HIV) infection or positive for HIV.
    6. Seropositive for surface antigen (HBsAg)
    7. virus (HCV) RNA positive.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
194 participants (actual)

Study arms

  • Active comparator
    Clazakizumab

    Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6 that is administered subcutaneously.

    Biological: Clazakizumab

  • Placebo comparator
    Placebo

    Physiologic saline solution that is administered subcutaneously.

    Drug: Physiologic saline solution

Interventions

  • BiologicalClazakizumab

    Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6

  • DrugPhysiologic saline solution

    Normal saline

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 52 in Estimated Glomerular Filtration Rate (eGFR)

    This primary outcome measure was the one from the first interim analysis.

    Time frame: From Baseline to Week 52

  2. Number of Participants With Composite All-cause Allograft Loss or Irreversible Loss of Allograft Function

    Composite all-cause allograft loss or irreversible loss of allograft function, defined as time to first occurrence of any of the following components: * eGFR \< 15 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2)\* * return to dialysis\* * allograft nephrectomy * retransplantation * death from any cause, or * a sustained (greater than or equal to \[\>=\] 60 days) 40% decline in eGFR from Baseline. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The number of participants with composite all-cause allograft loss or irreversible loss of allograft function are reported here. Time-to-event data were not calculated due to the study's termination.

    Time frame: From Baseline to 4 years

  3. Percentage of Participants With Composite All-cause Allograft Loss or Irreversible Loss of Allograft Function

    Composite all-cause allograft loss or irreversible loss of allograft function, defined as time to first occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy * retransplantation * death from any cause, or * a sustained (greater than or equal to \[\>=\] 60 days) 40% decline in eGFR from Baseline. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The percentage of participants with composite all-cause allograft loss or irreversible loss of allograft function are reported here.

    Time frame: From Baseline to 4 years

  4. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and Adverse Events of Special Interest (AESIs)

    Time frame: Up to 4 years

  5. Percentage of Participants With TEAEs, Serious TEAEs, and AESIs

    Time frame: Up to 4 years

  6. Number of Participants Who Tested Positive for Polyoma BK Virus (BKV), Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV)

    Number of participants who tested positive for BKV, CMV or EBV according to the maximum measured viral amount (International Units/mL \[IU/mL\]) after baseline are reported here.

    Time frame: From baseline up to 4 years

  7. Number of Participants With Abnormal Laboratory Test Results

    Laboratory tests included liver function test (LFTs), complete blood count (CBC), plasma lipids, high-sensitivity C-reactive protein (hsCRP). Only participants with abnormal laboratory test results are reported here. Here, ULN = upper limit of normal, LLN = lower limit of normal, ALT = Alanine aminotransferase and AST = Aspartate aminotransferase.

    Time frame: Up to 4 years

  8. Percentage of Participants With Abnormal Laboratory Test Results

    Laboratory tests included LFTs, CBC, plasma lipids, hsCRP. Only percentage of participants with abnormal laboratory test results are reported here. Here, ULN = upper limit of normal, LLN = lower limit of normal, ALT = Alanine aminotransferase and AST = Aspartate aminotransferase.

    Time frame: Up to 4 years

  9. Number of Participants With Clinically Significant Change in Vital Signs, Electrocardiograms (ECGs), and Physical Examination

    Time frame: Up to 4 years

  10. Number of Participants With Positive Anti-drug Antibodies

    Time frame: Baseline, Weeks 12, 24, and 48

  11. Percentage of Participants With Positive Anti-drug Antibodies

    Time frame: Baseline, Weeks 12, 24, and 48

Secondary outcomes

  1. Number of Participants With Composite All-cause Allograft Loss

    Composite all-cause allograft loss, defined as, time to first occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy * retransplantation, or * death from any cause. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The number of participants with composite all-cause allograft loss are reported here.

    Time frame: From Baseline to 4 years

  2. Percentage of Participants With Composite All-cause Allograft Loss

    Composite all-cause allograft loss, defined as, time to first occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy * retransplantation, or * death from any cause. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The percentage of participants with composite all-cause allograft loss are reported here.

    Time frame: From Baseline to 4 years

  3. Number of Participants With Irreversible Loss of Allograft Function

    Irreversible loss of allograft function as defined by a 40% decline in eGFR from Baseline sustained for at least 60 days.

    Time frame: From Baseline to 4 years

  4. Percentage of Participants With Irreversible Loss of Allograft Function

    Irreversible loss of allograft function as defined by a 40% decline in eGFR from Baseline sustained for at least 60 days.

    Time frame: From Baseline to 4 years

  5. Number of Participants With Death-censored Allograft Loss

    Time to death-censored allograft loss, was defined as occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy, or * retransplantation. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The number of participants with death-censored allograft loss are reported here.

    Time frame: From Baseline to 4 years

  6. Percentage of Participants With Death-censored Allograft Loss

    Death-censored allograft loss was defined as the occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy, or * retransplantation. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The percentage of participants who experienced death-censored allograft loss are reported here.

    Time frame: From Baseline to 4 years

  7. Change From Baseline in Urine Albumin Creatinine Ratio (UACR)

    Time frame: From Baseline to Week 52

  8. Percent Change From Baseline in Mean Fluorescent Intensity for Donor-Specific Antibodies (DSA)

    Time frame: From Baseline to Week 52

  9. Change From Baseline in Banff Lesion Grading Score (2015 Criteria) of Pre-treatment to Post-treatment (Week 52) Kidney Biopsies

    Banff lesion grading scores assess the presence and the degree of histopathological changes in the different compartments of kidney biopsies. Here, the improved category is defined as a decline in the Banff lesion grading score. Participants with improved scores, not improved scores, and missing biopsies for C4d staining, interstitial fibrosis, tubular atrophy, glomerular basement membrane double contours, glomerulitis and peritubular capillaritis are reported for this outcome measure.

    Time frame: From Baseline to Week 52

  10. Incidence of Acute Rejection Episodes of T Cell-mediated Rejection (TCMR) and Antibody-mediated Rejection (ABMR)

    Number of participants who had at least one acute rejection episode (TCMR or ABMR) are reported for this outcome measure.

    Time frame: Baseline up to End of treatment (up to approximately 4 years)

  11. Overall Participant Survival

    Number of participants who were alive up to Week 52 are reported for this outcome measure.

    Time frame: Up to Week 52

  12. Maximum Concentration at Steady State (Cmax ss) of CSL300

    A subset of participants (out of the enrolled participants in the main study) had the option to participate in a pharmacokinetic (PK)/ Pharmacodynamic (PD) sub-study.

    Time frame: Up to Week 24

  13. Trough Concentrations at Steady State (Ctrough ss) of CSL300

    A subset of participants (out of the enrolled participants in the main study) had the option to participate in a PK/PD sub-study.

    Time frame: Up to Week 24

  14. Area Under the Concentration-time Curve (AUC0-tau) at Steady State of CSL300

    A subset of participants (out of the enrolled participants in the main study) had the option to participate in a PK/PD sub-study.

    Time frame: Up to Week 24

  15. Time of Maximum Concentration at Steady State (Tmax ss) of CSL300

    A subset of participants (out of the enrolled participants in the main study) had the option to participate in a PK/PD sub-study.

    Time frame: Up to Week 24

07

Results

Posted Jul 23, 2025
Limitations and caveats
This study was not able to complete secondary endpoint assessments as planned. The study was terminated due to futility after the planned interim analysis based on the change in eGFR from baseline to Week 52 and analysis was conducted where feasible using the data collected at Week 52 or by the time of study termination.

Participant flow

The study was conducted at 139 study sites in 13 countries: Canada, United States, Austria, Czechia, France, Germany, Hungary, Netherlands, Spain, Sweden, Switzerland, Democratic People's Republic of Korea, and Australia.

Participant flow — Overall Study
MilestoneClazakizumabPlacebo
Started94100
Completed1615
Not completed7885
Withdrew: Withdrew consent18
Withdrew: Physician decision54
Withdrew: Sponsor decision (due to study termination)6871
Withdrew: Lost to follow-up01
Withdrew: Other-unspecified41

Outcome measures

PrimaryChange From Baseline to Week 52 in Estimated Glomerular Filtration Rate (eGFR)

This primary outcome measure was the one from the first interim analysis.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · milliliter per minute per 1.73 meter^2
Change From Baseline to Week 52 in Estimated Glomerular Filtration Rate (eGFR)
milliliter per minute per 1.73 meter^2ClazakizumabPlacebo
Change From Baseline to Week 52 in Estimated Glomerular Filtration Rate (eGFR)-8.0 (-10.2 to -5.8)-5.2 (-7.4 to -3.1)
Statistical analysis
  • Clazakizumab vs Placebo · Treatment difference: -2.75 · 95% CI -5.84 to 0.35
PrimaryNumber of Participants With Composite All-cause Allograft Loss or Irreversible Loss of Allograft Function

Composite all-cause allograft loss or irreversible loss of allograft function, defined as time to first occurrence of any of the following components: * eGFR \< 15 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2)\* * return to dialysis\* * allograft nephrectomy * retransplantation * death from any cause, or * a sustained (greater than or equal to \[\>=\] 60 days) 40% decline in eGFR from Baseline. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The number of participants with composite all-cause allograft loss or irreversible loss of allograft function are reported here. Time-to-event data were not calculated due to the study's termination.

Time frame:
From Baseline to 4 years
Reported as:
Count of participants · Participants
Number of Participants With Composite All-cause Allograft Loss or Irreversible Loss of Allograft Function
ParticipantsClazakizumabPlacebo
Number of Participants With Composite All-cause Allograft Loss or Irreversible Loss of Allograft Function2622
PrimaryPercentage of Participants With Composite All-cause Allograft Loss or Irreversible Loss of Allograft Function

Composite all-cause allograft loss or irreversible loss of allograft function, defined as time to first occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy * retransplantation * death from any cause, or * a sustained (greater than or equal to \[\>=\] 60 days) 40% decline in eGFR from Baseline. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The percentage of participants with composite all-cause allograft loss or irreversible loss of allograft function are reported here.

Time frame:
From Baseline to 4 years
Reported as:
Number · percentage of participants
Percentage of Participants With Composite All-cause Allograft Loss or Irreversible Loss of Allograft Function
percentage of participantsClazakizumabPlacebo
Percentage of Participants With Composite All-cause Allograft Loss or Irreversible Loss of Allograft Function28.322.2
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and Adverse Events of Special Interest (AESIs)
Time frame:
Up to 4 years
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and Adverse Events of Special Interest (AESIs)
ParticipantsClazakizumabPlacebo
TEAEs8988
Serious TEAEs3939
AESIs5652
PrimaryPercentage of Participants With TEAEs, Serious TEAEs, and AESIs
Time frame:
Up to 4 years
Reported as:
Number · percentage of participants
Percentage of Participants With TEAEs, Serious TEAEs, and AESIs
percentage of participantsClazakizumabPlacebo
TEAEs95.788.0
Serious TEAEs41.939.0
AESIs60.252.0
PrimaryNumber of Participants Who Tested Positive for Polyoma BK Virus (BKV), Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV)

Number of participants who tested positive for BKV, CMV or EBV according to the maximum measured viral amount (International Units/mL \[IU/mL\]) after baseline are reported here.

Time frame:
From baseline up to 4 years
Reported as:
Count of participants · Participants
Number of Participants Who Tested Positive for Polyoma BK Virus (BKV), Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV)
ParticipantsClazakizumabPlacebo
BKV >Lower limit of quantification (LLOQ) to <320 IU/mL32
BKV >=320 IU/mL to <3200 IU/mL10
BKV >=3200 IU/mL10
CMV >LLOQ to <1000 IU/mL51
CMV >=1000 IU/mL to <5000 IU/mL22
CMV >=5000 IU/mL00
EBV >LLOQ to <10200 IU/mL87
EBV >=10200 IU/mL to <20400 IU/mL00
EBV >=20400 IU/mL00
PrimaryNumber of Participants With Abnormal Laboratory Test Results

Laboratory tests included liver function test (LFTs), complete blood count (CBC), plasma lipids, high-sensitivity C-reactive protein (hsCRP). Only participants with abnormal laboratory test results are reported here. Here, ULN = upper limit of normal, LLN = lower limit of normal, ALT = Alanine aminotransferase and AST = Aspartate aminotransferase.

Time frame:
Up to 4 years
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Laboratory Test Results
ParticipantsClazakizumabPlacebo
ALT : >ULN to 3 x ULN156
ALT : > 3 to 5 × ULN01
AST : >ULN to 3 x ULN114
AST : > 3 to 5 × ULN10
AST : > 5 × ULN02
Bilirubin: > ULN to 2 × ULN206
Bilirubin: > 2 × ULN50
Neutrophils: < 2.5 to 1.5 10^9/L3321
Neutrophils: < 1.5 to 1.0 10^9/L155
Neutrophils: < 1.0 10^9/L70
Platelets: < LLN to 75.0 10^9/L3910
Platelets: < 75.0 to 50.0 10^9/L10
PrimaryPercentage of Participants With Abnormal Laboratory Test Results

Laboratory tests included LFTs, CBC, plasma lipids, hsCRP. Only percentage of participants with abnormal laboratory test results are reported here. Here, ULN = upper limit of normal, LLN = lower limit of normal, ALT = Alanine aminotransferase and AST = Aspartate aminotransferase.

Time frame:
Up to 4 years
Reported as:
Number · percentage of participants
Percentage of Participants With Abnormal Laboratory Test Results
percentage of participantsClazakizumabPlacebo
ALT : >ULN to 3 x ULN16.16.1
ALT : > 3 to 5 × ULN01.0
AST : >ULN to 3 x ULN11.84.0
AST : > 3 to 5 × ULN1.10
AST : > 5 × ULN02.0
Bilirubin: > ULN to 2 × ULN21.56.1
Bilirubin: > 2 × ULN5.40
Neutrophils: < 2.5 to 1.5 10^9/L35.521.2
Neutrophils: < 1.5 to 1.0 10^9/L16.15.1
Neutrophils: < 1.0 10^9/L7.50
Platelets: < LLN to 75.0 10^9/L41.910.1
Platelets: < 75.0 to 50.0 10^9/L1.10
PrimaryNumber of Participants With Clinically Significant Change in Vital Signs, Electrocardiograms (ECGs), and Physical Examination
Time frame:
Up to 4 years
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change in Vital Signs, Electrocardiograms (ECGs), and Physical Examination
ParticipantsClazakizumabPlacebo
Number of Participants With Clinically Significant Change in Vital Signs, Electrocardiograms (ECGs), and Physical Examination00
PrimaryNumber of Participants With Positive Anti-drug Antibodies
Time frame:
Baseline, Weeks 12, 24, and 48
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-drug Antibodies
ParticipantsClazakizumabPlacebo
Baseline510
Week 1238
Week 2427
Week 4804
PrimaryPercentage of Participants With Positive Anti-drug Antibodies
Time frame:
Baseline, Weeks 12, 24, and 48
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Anti-drug Antibodies
percentage of participantsClazakizumabPlacebo
Baseline5.710.3
Week 124.19.8
Week 242.99.7
Week 4807.7
SecondaryNumber of Participants With Composite All-cause Allograft Loss

Composite all-cause allograft loss, defined as, time to first occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy * retransplantation, or * death from any cause. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The number of participants with composite all-cause allograft loss are reported here.

Time frame:
From Baseline to 4 years
Reported as:
Count of participants · Participants
Number of Participants With Composite All-cause Allograft Loss
ParticipantsClazakizumabPlacebo
Number of Participants With Composite All-cause Allograft Loss1714
SecondaryPercentage of Participants With Composite All-cause Allograft Loss

Composite all-cause allograft loss, defined as, time to first occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy * retransplantation, or * death from any cause. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The percentage of participants with composite all-cause allograft loss are reported here.

Time frame:
From Baseline to 4 years
Reported as:
Number · percentage of participants
Percentage of Participants With Composite All-cause Allograft Loss
percentage of participantsClazakizumabPlacebo
Percentage of Participants With Composite All-cause Allograft Loss18.514.1
SecondaryNumber of Participants With Irreversible Loss of Allograft Function

Irreversible loss of allograft function as defined by a 40% decline in eGFR from Baseline sustained for at least 60 days.

Time frame:
From Baseline to 4 years
Reported as:
Count of participants · Participants
Number of Participants With Irreversible Loss of Allograft Function
ParticipantsClazakizumabPlacebo
Number of Participants With Irreversible Loss of Allograft Function2218
SecondaryPercentage of Participants With Irreversible Loss of Allograft Function

Irreversible loss of allograft function as defined by a 40% decline in eGFR from Baseline sustained for at least 60 days.

Time frame:
From Baseline to 4 years
Reported as:
Number · percentage of participants
Percentage of Participants With Irreversible Loss of Allograft Function
percentage of participantsClazakizumabPlacebo
Percentage of Participants With Irreversible Loss of Allograft Function23.918.2
SecondaryNumber of Participants With Death-censored Allograft Loss

Time to death-censored allograft loss, was defined as occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy, or * retransplantation. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The number of participants with death-censored allograft loss are reported here.

Time frame:
From Baseline to 4 years
Reported as:
Count of participants · Participants
Number of Participants With Death-censored Allograft Loss
ParticipantsClazakizumabPlacebo
Number of Participants With Death-censored Allograft Loss1613
SecondaryPercentage of Participants With Death-censored Allograft Loss

Death-censored allograft loss was defined as the occurrence of any of the following components: * eGFR \< 15 mL/min/1.73 m\^2\* * return to dialysis\* * allograft nephrectomy, or * retransplantation. (\*Total cumulative duration of sustained eGFR \< 15 mL/min/1.73 m\^2 AND / OR dialysis \>= 60 days.) If the eGFR \< 15 mL/min/1.73 m\^2 was the only component reached, the value must be sustained over at least 60 days and must be confirmed by a repeat measurement after \>= 60 days from the first measurement. The percentage of participants who experienced death-censored allograft loss are reported here.

Time frame:
From Baseline to 4 years
Reported as:
Number · percentage of participants
Percentage of Participants With Death-censored Allograft Loss
percentage of participantsClazakizumabPlacebo
Percentage of Participants With Death-censored Allograft Loss17.413.1
SecondaryChange From Baseline in Urine Albumin Creatinine Ratio (UACR)
Time frame:
From Baseline to Week 52
Reported as:
Mean · gram per mole
Change From Baseline in Urine Albumin Creatinine Ratio (UACR)
gram per moleClazakizumabPlacebo
Change From Baseline in Urine Albumin Creatinine Ratio (UACR)50.734 ± 125.562831.178 ± 112.8894
SecondaryPercent Change From Baseline in Mean Fluorescent Intensity for Donor-Specific Antibodies (DSA)
Time frame:
From Baseline to Week 52
Reported as:
Median · percent change
Percent Change From Baseline in Mean Fluorescent Intensity for Donor-Specific Antibodies (DSA)
percent changeClazakizumabPlacebo
DSA Class I-23.20 (-53.34 to -4.54)-39.71 (-69.67 to -20.22)
DSA Class II-27.15 (-46.32 to -5.05)-13.68 (-26.69 to -1.75)
SecondaryChange From Baseline in Banff Lesion Grading Score (2015 Criteria) of Pre-treatment to Post-treatment (Week 52) Kidney Biopsies

Banff lesion grading scores assess the presence and the degree of histopathological changes in the different compartments of kidney biopsies. Here, the improved category is defined as a decline in the Banff lesion grading score. Participants with improved scores, not improved scores, and missing biopsies for C4d staining, interstitial fibrosis, tubular atrophy, glomerular basement membrane double contours, glomerulitis and peritubular capillaritis are reported for this outcome measure.

Time frame:
From Baseline to Week 52
Reported as:
Count of participants · Participants
Change From Baseline in Banff Lesion Grading Score (2015 Criteria) of Pre-treatment to Post-treatment (Week 52) Kidney Biopsies
ParticipantsClazakizumabPlacebo
C4d Staining — Improved score1010
C4d Staining — Not improved score1721
C4d Staining — Missing biopsies6568
Interstitial Fibrosis — Improved score38
Interstitial Fibrosis — Not improved score2423
Interstitial Fibrosis — Missing biopsies6568
Tubular Atrophy — Improved score15
Tubular Atrophy — Not improved score2626
Tubular Atrophy — Missing biopsies6568
Glomerular Basement Membrane Double Contours — Improved score610
Glomerular Basement Membrane Double Contours — Not improved score2121
Glomerular Basement Membrane Double Contours — Missing biopsies6568
Glomerulitis — Improved score1417
Glomerulitis — Not improved score1314
Glomerulitis — Missing biopsies6568
Peritubular Capillaritis — Improved score1415
Peritubular Capillaritis — Not improved score1316
Peritubular Capillaritis — Missing biopsies6568
SecondaryIncidence of Acute Rejection Episodes of T Cell-mediated Rejection (TCMR) and Antibody-mediated Rejection (ABMR)

Number of participants who had at least one acute rejection episode (TCMR or ABMR) are reported for this outcome measure.

Time frame:
Baseline up to End of treatment (up to approximately 4 years)
Reported as:
Count of participants · Participants
Incidence of Acute Rejection Episodes of T Cell-mediated Rejection (TCMR) and Antibody-mediated Rejection (ABMR)
ParticipantsClazakizumabPlacebo
Incidence of Acute Rejection Episodes of T Cell-mediated Rejection (TCMR) and Antibody-mediated Rejection (ABMR)23
SecondaryOverall Participant Survival

Number of participants who were alive up to Week 52 are reported for this outcome measure.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Overall Participant Survival
ParticipantsClazakizumabPlacebo
Overall Participant Survival9098
SecondaryMaximum Concentration at Steady State (Cmax ss) of CSL300

A subset of participants (out of the enrolled participants in the main study) had the option to participate in a pharmacokinetic (PK)/ Pharmacodynamic (PD) sub-study.

Time frame:
Up to Week 24
Reported as:
Geometric mean · nanograms per milliliter
Maximum Concentration at Steady State (Cmax ss) of CSL300
nanograms per milliliterClazakizumab
Maximum Concentration at Steady State (Cmax ss) of CSL3003556.8 ± 10.5
SecondaryTrough Concentrations at Steady State (Ctrough ss) of CSL300

A subset of participants (out of the enrolled participants in the main study) had the option to participate in a PK/PD sub-study.

Time frame:
Up to Week 24
Reported as:
Geometric mean · nanograms per milliliter
Trough Concentrations at Steady State (Ctrough ss) of CSL300
nanograms per milliliterClazakizumab
Trough Concentrations at Steady State (Ctrough ss) of CSL3002366.8 ± 9.2
SecondaryArea Under the Concentration-time Curve (AUC0-tau) at Steady State of CSL300

A subset of participants (out of the enrolled participants in the main study) had the option to participate in a PK/PD sub-study.

Time frame:
Up to Week 24
Reported as:
Geometric mean · days*nanograms per milliliter
Area Under the Concentration-time Curve (AUC0-tau) at Steady State of CSL300
days*nanograms per milliliterClazakizumab
Area Under the Concentration-time Curve (AUC0-tau) at Steady State of CSL30078080.34636 ± 7.19614
SecondaryTime of Maximum Concentration at Steady State (Tmax ss) of CSL300

A subset of participants (out of the enrolled participants in the main study) had the option to participate in a PK/PD sub-study.

Time frame:
Up to Week 24
Reported as:
Median · day
Time of Maximum Concentration at Steady State (Tmax ss) of CSL300
dayClazakizumab
Time of Maximum Concentration at Steady State (Tmax ss) of CSL3006.92292 (4.9986 to 11.9299)

Adverse events

Collected over Up to 4 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Clazakizumab3/93 (3.2%)39/93 (41.9%)81/93 (87.1%)
Placebo1/100 (1%)39/100 (39%)80/100 (80%)
Most frequent serious events
Showing 10 of 108
Most frequent serious events
EventClazakizumabPlacebo
COVID-19Infections and infestations13/9310/100
Acute kidney injuryRenal and urinary disorders13/936/100
DiarrhoeaGastrointestinal disorders4/933/100
PneumoniaInfections and infestations3/931/100
AnaemiaBlood and lymphatic system disorders3/932/100
COVID-19 pneumoniaInfections and infestations2/931/100
Clostridium difficile infectionInfections and infestations2/930/100
Urinary tract infectionInfections and infestations2/930/100
Renal impairmentRenal and urinary disorders2/931/100
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/930/100
Most frequent other events
Showing 10 of 43
Most frequent other events
EventClazakizumabPlacebo
COVID-19Infections and infestations28/9330/100
Oedema peripheralGeneral disorders24/9311/100
DiarrhoeaGastrointestinal disorders21/9322/100
AnaemiaBlood and lymphatic system disorders16/9316/100
NeutropeniaBlood and lymphatic system disorders15/930/100
HyperkalaemiaMetabolism and nutrition disorders12/9313/100
Blood creatinine increasedInvestigations9/9313/100
HypertensionVascular disorders12/9313/100
Urinary tract infectionInfections and infestations12/936/100
NauseaGastrointestinal disorders11/936/100

Baseline characteristics

Analysis was performed on randomized set, which included all participants who were randomized.

Age, Continuous
Age, Continuous(years)ClazakizumabPlaceboTotal
Mean46.3 ± 11.8747.0 ± 12.2446.7 ± 12.04
Sex: Female, Male
Sex: Female, Male(Participants)ClazakizumabPlaceboTotal
Female292655
Male6574139
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ClazakizumabPlaceboTotal
Ethnicity — Not Hispanic, Latino/a or of Spanish origin6978147
Ethnicity — Hispanic, Latino/a or of Spanish origin181634
Ethnicity — Not reported549
Ethnicity — Unknown224
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ClazakizumabPlaceboTotal
Race — White6269131
Race — Black or African American10717
Race — Korean91322
Race — Other6814
Race — Asian Indian314
Race — Other Asian213
Race — American or Alaskan Native101
Race — Filipino101
Race — Missing011
08

Study locations

142 sites
  • University of Alabama at Birmingham (UAB) - University of Alabama Hospital (UAB Hospital)
    Birmingham, Alabama 35294, United States
  • Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
  • Keck Medical Center Of USC
    Los Angeles, California 90033, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • UCLA Kidney Transplant Research Program
    Los Angeles, California 90095, United States
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • California Institute of Renal Research
    San Diego, California 92123, United States
  • North America Research Institute
    San Dimas, California 91773, United States
  • California Pacific Medical Center
    San Francisco, California 94109, United States
  • Kaiser Permanente
    San Francisco, California 94118, United States
  • University of California, San Francisco Medical Center
    San Francisco, California 94143, United States
  • University Of Colorado Hospital - Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • Tampa General Medical Group
    Tampa, Florida 33606, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Rush University Medical Center - University Cardiovascular Surgeons
    Chicago, Illinois 60612, United States
  • Indiana University (IU) Health Physicians - Kidney Diseases Clinic - Medical Diagnostic Center Location
    Indianapolis, Indiana 46202, United States
  • Unity Point Health
    Des Moines, Iowa 50309, United States
  • Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • University of Louisville Research Foundation
    Louisville, Kentucky 40202, United States
  • Tulane University Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Massachusetts General Cancer Center
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic
    Rochester, Minnesota 55095, United States
  • Washington University School of Medicine - Infectious Diseases (WU ID) Clinic
    St Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68105, United States
  • Saint Barnabas Medical Center
    Livingston, New Jersey 07039, United States
  • Erie County Medical Center Corp.
    Buffalo, New York 14215, United States
  • NYU Langone Medical Center
    New York, New York 10016, United States
  • New York Presbyterian Hospital / Weill Cornell Medical Center
    New York, New York 10021, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Duke Cancer Institute
    Durham, North Carolina 27710, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • The Ohio State University, Comprehensive Transplant Center
    Columbus, Ohio 43210, United States
  • University of Cincinnati
    Toledo, Ohio 43614, United States
  • Integris Baptist Medical Center
    Oklahoma City, Oklahoma 73112, United States
  • Lehigh Valley Health Network
    Allentown, Pennsylvania 18103, United States
  • Central Pennsylvania Transplant Foundation
    Harrisburg, Pennsylvania 17104, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02906, United States
  • Renal Disease Research Institute
    Dallas, Texas 75204, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75235, United States
  • Methodist Healthcare System of San Antonio
    San Antonio, Texas 78229, United States
  • VCU Health
    Richmond, Virginia 23298, United States
  • University of Washington
    Seattle, Washington 98195, United States
  • University of Wisconsin School of Medicine and Public Health (UWSMPH)
    Madison, Wisconsin 53705, United States
  • Medical College of WI Froedtert Hospital
    Milwaukee, Wisconsin 53226, United States
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • WSLHD, Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • The University of Queensland - Princess Alexandra Hospital (PAH)
    Woolloongabba, Queensland 4102, Australia
  • Monash Health Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • The Royal Melbourne Hospital
    Parkville, Victoria 3064, Australia
  • Sir Charles Gairdner Hospital (SCGH)
    Nedlands, Western Australia 6009, Australia
  • Royal Adelaide Hospital
    Adelaide, Australia
  • Royal Prince Alfred Hospital
    Camperdown, Australia
  • Monash Medical Centre
    Clayton, Australia
  • Linear Clinical Research
    Nedlands, Australia
  • Westmead Hospital
    Westmead, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Australia
  • LKH-Universität Hospital Graz
    Graz, Austria
  • Universitätsklinik für Innere Medizin III Innsbruck
    Innsbruck, Austria
  • Medizinische Universität Wien, Allgemeines Krankenhaus der S
    Vienna, Austria
  • UZ Antwerpen
    Edegem, Belgium
  • UZ Leuven
    Leuven, Belgium
  • Centre Hospitalier Universitaire Sart Tilman
    Liège, Belgium
  • Vancouver General Hospital - Gordon & Leslie Diamond Centre
    Vancouver, British Columbia V5Z 1M9, Canada
  • St. Paul's Hospital, Providence Health Care, Univ. Of British Columbia
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Shared Health Inc. operating as the Health Sciences Centre
    Winnipeg, Manitoba R3A 1R9, Canada
  • Queen Elizabeth II Health Sciences Centre
    Halifax, Nova Scotia B3H 1V7, Canada
  • London Health Sciences Centre
    London, Ontario N6A 5A5, Canada
  • St. Michael's Health Centre
    Toronto, Ontario M5C 2T2, Canada
  • McGill University Health Center
    Montreal, Quebec H4A 3J1, Canada
  • St Paul's Hospital Foundation
    Saskatoon, Saskatchewan S7M 0Z9, Canada
  • Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM)
    Montreal, Canada
  • University Health Network
    Toronto, Canada
  • Centrum kardiovaskulární a transplantacní chirurgie Brno
    Brno-střed, Czechia
  • Fakultní Nemocnice Olomouc
    Olomouc, Czechia
  • IKEM
    Prague, 14000, Czechia
  • CHU GRENOBLE ALPES - Consultation Néphrologie Bureau des ARC (Côté Chartreuse, Rez-de-Chaussée Haut)
    Grenoble, Grenoble Cédex 09 38043, France
  • Néphrologie - Pavillon Sainte Venise - CHU de Rouen - Hôpital de Bois Guillaume
    Bois-Guillaume, 76230, France
  • Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin
    Bordeaux, 33076, France
  • Centre Hospitalier Universitaire (CHU) - Hopital Henri Mondor
    Créteil, 94010, France
  • Hopital Kremlin Bicetre
    Le Kremlin-Bicêtre, 94270, France
  • Centre Hospitalier Universitaire (CHU) De Limoges Hopital Dupuytren
    Limoges, 87042, France
  • Hopital Edouard Herriot
    Lyon, 69003, France
  • Hopital de la Conception - APHM
    Marseille, 13005, France
  • Centre Hospitalier Regional Universitaire (CHRU) Montpellier Arnaud de Villeneuve
    Montpellier, 34295, France
  • CHU de Nantes - Houtel Dieu
    Nantes, 44093, France
  • Centre Hospitalier Universitaire de Nice, Hopital Pasteur 2
    Nice, 06001, France
  • Hospital Saint-Louis - APHP
    Paris, 75010, France
  • Hopital Necker Enfants Malades
    Paris, 75015, France
  • Centre Hospitalier Universitaire de Poitiers
    Poitiers, 86021, France
  • Hopitaux Universitaire de Strasbourg-Centre de References des Maladies Autoimmunes
    Strasbourg, 67098, France
  • CHU Rangueil
    Toulouse, 31059, France
  • Centre Hospitalier Regional Universitaire de Tours (CHRU de Tours) - Hopital Bretonneau
    Tours, 37044, France
  • Charite - Universitaetsmedizin Berlin - Campus Charite Mitte (CCM)
    Berlin, 10117, Germany
  • Debreceni Egyetem, Klinikai Központ, Auguszta
    Debrecen, 4032, Hungary

Showing the first 100 of 142 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Mayer KA, Budde K, Diebold M, Halloran PF, Bohmig GA. Targeting CD38 in Antibody-Mediated Rejection. Transpl Int. 2025 May 15;38:14343. doi: 10.3389/ti.2025.14343. eCollection 2025. PubMed 40444214 ↗
  • Mannon RB, Vincenti FG. Poised for Innovation: Considerations for End Points for New Drug Development in Kidney Transplantation. J Am Soc Nephrol. 2024 Nov 1;35(11):1603-1606. doi: 10.1681/ASN.0000000000000475. Epub 2024 Aug 5. No abstract available. PubMed 39102302 ↗
  • Nickerson PW, Bohmig GA, Chadban S, Kumar D, Mannon RB, van Gelder T, Lee JC, Adler S, Chong E, Djamali A. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design. Trials. 2022 Dec 22;23(1):1042. doi: 10.1186/s13063-022-06897-3. PubMed 36550562 ↗
  • Borski A, Eskandary F, Haindl S, Doberer K, Muhlbacher J, Mayer KA, Budde K, Halloran PF, Chong E, Jilma B, Bohmig GA, Wahrmann M. Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Renal Allograft Rejection: Accumulation of Antibody-neutralized Interleukin-6 Without Signs of Proinflammatory Rebound Phenomena. Transplantation. 2023 Feb 1;107(2):495-503. doi: 10.1097/TP.0000000000004285. Epub 2023 Jan 26. PubMed 35969004 ↗
  • Jordan SC, Ammerman N, Choi J, Huang E, Najjar R, Peng A, Sethi S, Sandhu R, Atienza J, Toyoda M, Ge S, Lim K, Gillespie M, Zhang X, Haas M, Vo A. Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts. Kidney Int Rep. 2022 Feb 9;7(4):720-731. doi: 10.1016/j.ekir.2022.01.1074. eCollection 2022 Apr. PubMed 35497778 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (ie FDA, EMA) is complete and the primary publication is available.

Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Apr 2024, 53 months.

Results were first posted in Jul 2025, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2018
First posted
Nov 19, 2018
StartActual
Oct 14, 2019
Primary completionActual
Apr 8, 2024
CompletionActual
Apr 8, 2024
Results first posted
Jul 23, 2025
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03744910
Lead sponsor
CSL Behring
Collaborators
ICON Clinical Research
Responsible party
Sponsor
First posted
Nov 19, 2018
Start date
Oct 14, 2019
Primary completion
Apr 8, 2024
Completion
Apr 8, 2024
Results posted
Jul 23, 2025
Last update
Jul 23, 2025

Study contacts

Study Director
study director · CSL Behring

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clazakizumab

Start the discussion